Tobacco use is inextricably linked to a number of health risks both in the general and HIV-infected populations. There is, however, a dearth of research on effective tobacco control programs among people living with HIV, and especially among adolescents, young adults and pregnant women, groups with heightened or increased vulnerability secondary to tobacco use. Adolescents and young adults constitute a growing population of persons living with HIV infection. Early and continued tobacco use in this population living with a disease characterized by premature onset multimorbidity and chronic inflammation is of concern. Additionally, there is an increased acuity for tobacco control among HIV-infected pregnant women to reduce pregnancy morbidity and improve fetal outcome. This review will provide an important summary of current knowledge of tobacco use among HIV-infected adolescents, young adults and pregnant women. The effects of tobacco use in these specific populations will be presented and the current state of tobacco control within these populations, assessed.
References
[1]
Center for Disease Control and Prevention (CDC). HIV in the United States: At a Glance. Available online: http://www.cdc.gov/hiv/resources/factsheets/us.htm (accessed on 18 March 2013).
[2]
Center for Disease Control and Prevention (CDC). HIV surveillance, United States, 1981-2008. MMWR Morb. Mortal. Wkly. 2011, 60, 689–723.
[3]
Center for Disease Control and Prevention (CDC). HIV among Youth in the US. Available online: http://www.cdc.gov/vitalsigns/HIVAmongYouth/index.html (accessed on 18 March 2013).
[4]
Sharma, A.; Feldman, J.G.; Golub, E.T.; Schmidt, J.; Silver, S.; Robinson, E.; Minkoff, H. Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am. J. Obstet. Gynecol. 2007, 196, doi:10.1016/j.ajog.2007.01.005.
[5]
Palella, F.J., Jr.; Delaney, K.M.; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.; Holmberg, S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338, 853–860, doi:10.1056/NEJM199803263381301.
[6]
Palella, F.J.; Baker, R.K.; Moorman, A.C.; Chmiel, J.S.; Wood, K.C.; Brooks, J.T.; Holmberg, S.D. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 2006, 43, 27–34, doi:10.1097/01.qai.0000233310.90484.16.
[7]
Bhaskaran, K.; Hamouda, O.; Sannes, M.; Boufassa, F.; Johnson, A.M.; Lambert, P.C.; Porter, K. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008, 300, 51–59, doi:10.1001/jama.300.1.51.
[8]
Hogg, R.; Samji, H.; Cescon, A.; Modur, S.; Napravnik, S.; Martin, J.; Gill, J.; Klein, M.; Kirk, G.; Gange, T. Temporal Changes in Life Expectancy of HIV+ Individuals: North America. In Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 5-8 March 2012; p. 137.
[9]
Jaggy, C.; von Overbeck, J.; Ledergerber, B.; Schwarz, C.; Egger, M.; Rickenbach, M.; Furrer, H.J.; Telenti, A.; Battegay, M.; Flepp, M.; et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003, 362, 877–878, doi:10.1016/S0140-6736(03)14307-3.
[10]
Crum, N.F.; Riffenburgh, R.H.; Wegner, S.; Agan, B.K.; Tasker, S.A.; Spooner, K.M.; Armstrong, A.W.; Fraswer, S.; Wallace, M.R. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J. Acquir. Immune Defic. Syndr. 2006, 41, 194–200, doi:10.1097/01.qai.0000179459.31562.16.
[11]
Krentz, H.B.; Kliewer, G.; Gill, M.J. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005, 6, 99–106, doi:10.1111/j.1468-1293.2005.00271.x.
[12]
El-Sadr, W.; Lundgren, J.D.; Neaton, J.D.; Gordin, F.; Abrams, D.; Arduino, R.C.; Babiker, A.; Burman, W.; Clumeck, N.; Cohen, C.J.; et al. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 2006, 355, 2283–2296, doi:10.1056/NEJMoa062360.
[13]
Hsue, P.Y.; Hunt, P.W.; Schnell, A.; Kalapus, S.C.; Hoh, R.; Ganz, P.; Martin, J.N.; Deeks, S.G. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009, 23, 1059–1067, doi:10.1097/QAD.0b013e32832b514b.
[14]
Tien, P.C.; Choi, A.I.; Zolopa, A.R.; Benson, C.; Tracy, R.; Scherzer, R.; Bacchetti, P.; Shlipak, M.; Grunfeld, C. Inflammation and mortality in HIV-infected adults: Analysis of the FRAM study cohort. J. Aacquir. Immune Def. Syndr. 2010, 55, 316–322, doi:10.1097/QAI.0b013e3181e66216.
[15]
Neuhaus, J.; Jacobs, D.R.; Baker, J.V.; Calmy, A.; Duprez, D.; La Rosa, A.; Kuller, L.H.; Pett, S.L.; Ristola, M.; Ross, M.J.; et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 2010, 201, 1788–1795, doi:10.1086/652749.
[16]
Rajasuriar, R.; Khoury, G.; Kamarulzaman, A.; French, M.A.; Cameron, P.U.; Lewin, S.R. Persistent immune activation in chronic HIV infection: Do any interventions work? AIDS , 2013, doi:10.1097/QAD.0b013e32835ecb8b.
[17]
Center for Disease Control and Prevention (CDC). Tobacco Use: Targeting the Nation’s Leading Killer at A Glance. 2011. Available online: http://www.cdc.gov/chronicdisease/resources/publications/aag/osh.htm (accessed 20 March 2013).
[18]
United States Department of Health and Human Services. US Surgeon General’s Report: Preventing Tobacco Use among Youth and Young Adults. 2012. Available online: www.surgeongeneral.gov/library/reports/preventing-youth-tobaccouse/ (accessed on 25 February 2013).
[19]
Ortega, G.; Castellà, C.; Martín-Cantera, C.; Ballve, J.L.; Diaz, E.; Saez, M.; Lozano, J.; Rofes, L.; Morera, C.; Barcelo, A.; et al. Passive smoking in babies: The BIBE study (Brief Intervention in babies. Effectiveness). BMC Public Health 2010, 10, 772, doi:10.1186/1471-2458-10-772.
[20]
United States Department of Health and Human Services. Summary Health Statistics for US Adults: National Health Interview Survey. 2011. Available online: http://www.cdc.gov/nchs/data/series/sr_10/sr10_256.pdf (accessed on 25 February 2013).
[21]
Niaura, R.; Shadel, W.G.; Morrow, K.; Tashima, K.; Flanigan, T.; Abrams, D.B. Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now. Clin. Infect. Dis. 2000, 31, 808–812, doi:10.1086/314048.
[22]
Rahmanian, S.; Wewers, M.E.; Koletar, S.; Reynolds, N.; Ferketich, A.; Diaz, P. Cigarette smoking in the HIV-infected population. Proc. Am. Thorac. Soc. 2011, 8, 313–319.
[23]
Pines, H.; Koutsky, L.; Buskin, S. Cigarette smoking and mortality among HIV-infected individuals in Seattle, Washington (1996–2008). AIDS Behav. 2011, 15, 243–251.
[24]
Webb, M.S.; Vanable, P.; Carey, M.P.; Blair, D.C. Cigarette smoking among HIV+ men and women: Examining health, substance use, and psychosocial correlates across the smoking spectrum. J. Behav. Med. 2007, 30, 371–383, doi:10.1007/s10865-007-9112-9.
[25]
Elkington, K.S.; Bauermeister, J.A.; Brackis-Cott, E.; Dolezal, C.; Mellins, C.A. Substance use and sexual risk behaviors in perinatally human immunodeficiency virus-exposed youth: Roles of caregivers, peers and HIV status. J. Adolesc. Health 2009, 45, 133–141, doi:10.1016/j.jadohealth.2009.01.004.
[26]
Wilson, C.M.; Houser, J.; Partlow, C.; Rudy, B.J.; Futterman, D.C.; Friedman, L.B. The REACH (Reaching for Excellence in Adolescent Care and Health) Project: Study design, methods, and population profile. J. Adolesc. Health 2001, 29S, 8–18.
[27]
Chatterton-Krchmeier, S.; Chakraborty, R.; Camacho-Gonzalez, A.; Batisky, D. Hypertension in HIV-infected Children and Adolescents. In Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, USA, 3–6 March 2012; p. 962.
[28]
Center for Disease Control and Prevention (CDC). Trends in smoking before, during, and after pregnancy—Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000–2005. MMWR Morb. Mortal. Wkly. Rep. 2009, 58, 1–29.
[29]
Stratton, P.; Tuomala, R.E.; Abboud, R.; Rodriguez, E.; Rich, K.; Pitt, J.; Diaz, C.; Hammill, H.; Minkoff, H. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: A report of the women and infants transmission study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1999, 20, 179–186, doi:10.1097/00042560-199902010-00011.
[30]
Turner, B.J.; Hauck, W.W.; Fanning, T.R.; Markson, L.E. Cigarette smoking and maternal-child HIV transmission. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997, 14, 327–337, doi:10.1097/00042560-199704010-00004.
[31]
Aliyu, M.H.; Weldeselasse, H.; August, E.M.; Keith, L.G.; Salihu, H.M. Cigarette smoking and fetal morbidity outcomes in a large cohort of HIV-infected mothers. Nicotine Tob. Res. 2013, 15, 177–184, doi:10.1093/ntr/nts105.
[32]
Guaraldi, G.; Orlando, G.; Zona, S.; Menozzi, M.; Carli, F.; Garlassi, E.; Berti, A.; Rossi, E.; Roverato, A.; Palella, F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin. Infect. Dis. 2011, 53, 1120–1126, doi:10.1093/cid/cir627.
[33]
Stead, L.F.; Lancaster, T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst. Rev. , 2012, doi:10.1002/14651858.CD008286.pub2.
[34]
Niaura, R.; Chander, G.; Hutton, H.; Stanton, C. Interventions to address chronic disease and HIV: Strategies to promote smoking cessation among HIV-infected individuals. Curr. HIV/AIDS Rep. 2012, 9, 375–384, doi:10.1007/s11904-012-0138-4.
[35]
Reynolds, N.R. Cigarette smoking and HIV: More evidence for action. AIDS Educ. Prev. 2009, 21, 106–121, doi:10.1521/aeap.2009.21.3_supp.106.
[36]
United States Department of Health and Human Services. US Surgeon General’s Report: The Health Benefits of Smoking Cessation. 1990. Available online: http://profiles.nlm.nih.gov/ps/retrieve/ResourceMetadata/NNBBCT (accessed on 18 March 2013).
[37]
Petoumenos, K.; Worm, S.; Reiss, P.; de Wit, S.; d’Arminio Monforte, A.; Sabin, C.; Friis-Mooler, N.; Weber, R.; Mercie, P.; Pradier, C.; et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D:A:D study. HIV Med. 2011, 12, 412–421, doi:10.1111/j.1468-1293.2010.00901.x.
[38]
Center for Disease Control and Prevention (CDC). Tobacco Use and Pregnancy. Available online: http://www.cdc.gov/reproductivehealth/tobaccousepregnancy/ (accessed 10 March 2013).
[39]
Campaign for Tobacco-Free Kids. The Path of Smoking Addiction Starts at Very Young Ages. Available online: http://www.tobaccofreekids.org/research/factsheets/pdf/0127.pdf (accessed 24 March 2013).
[40]
Vidrine, D.J.; Arduino, R.C.; Lazev, A.B.; Gritz, E.R. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS 2006, 20, 253–260, doi:10.1097/01.aids.0000198094.23691.58.
[41]
Vidrine, D.J.; Marks, R.M.; Arduino, R.C.; Gritz, E.R. Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-Month outcomes. Nicotine Tob. Res. 2012, 14, 106–110.
[42]
Kendrick, J.S.; Zahniser, S.C.; Miller, N.; Salas, N.; Stine, J.; Gargiullo, P.M.; Floyd, R.L.; Spierto, F.W.; Sexton, M.; Metzger, R.W.; et al. Integrating smoking cessation into routine public prenatal care: The smoking cessation in pregnancy project. Am. J. Public Health 1995, 85, 217–222, doi:10.2105/AJPH.85.2.217.
[43]
Britton, G.R.; Brinthaupt, J.; Stehle, J.M.; James, G.D. Comparison of self-reported smoking and urinary cotinine levels in a rural pregnant population. J. Obstet. Gynecol. Neonatal Nurs. 2004, 33, 306–311.
[44]
Center for Disease Control and Prevention (CDC). Tobacco Cessation during Pregnancy: Prevalence and Interventions. Available online: http://www.hhs.gov/opa/pdfs/slides-10-21-2009-health.pdf (accessed on 18 March 2013).
[45]
Lambert, J.S.; Watts, D.H.; Mofenson, L. Risk factors for preterm birth , low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. AIDS 2000, 14, 1389–1399, doi:10.1097/00002030-200007070-00012.
[46]
Tassiopoulos, K.; Read, J.S.; Brogly, S.; Rich, K.; Lester, B.; Spector, S.A.; Yogev, R. Substance use in HIV-Infected women during pregnancy: Self-report versus meconium analysis. AIDS Behav. 2011, 14, 1269–1278.
[47]
Currier, J.S.; Taylor, A.; Boyd, F. Coronary heart disease in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 2003, 33, 506–512, doi:10.1097/00126334-200308010-00012.
[48]
Triant, V.A.; Lee, H.; Hadigan, C.; Grinspoon, S.K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. MeTable 2007, 92, 2506–2512, doi:10.1210/jc.2006-2190.
[49]
Chow, F.C.; Regan, S.; Feske, S.; Meigs, J.B.; Grinspoon, S.K.; Triant, V.A. Comparison of ischemic stroke incidence in HIV-infected and non—HIV-infected patients in a US health care system. J. Acquir. Immune Defic. Syndr. 2012, 60, 351–358, doi:10.1097/QAI.0b013e31825c7f24.
[50]
Shinton, R.; Beevers, G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989, 298, 789–794, doi:10.1136/bmj.298.6676.789.
[51]
Ye, Y.; Zeng, Y.; Li, X. HIV infection: An independent risk factor of peripheral arterial disease. J. Acquir. Immune Defic. Syndr. 2010, 53, 276–278, doi:10.1097/QAI.0b013e3181ba1c31.
[52]
Kirk, G.D.; Merlo, C.; O’Driscoll, P. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin. Infect. Dis. 2007, 45, 103–110, doi:10.1086/518606.
[53]
Castellsague, X.; Munoz, N. Chapter 3: Cofactors in human papillomavirus carcinogenesis—Role of parity, oral contraceptives, and tobacco smoking. J. Natl. Cancer Inst. Monogr. 2003, 31, 20–28, doi:10.1093/oxfordjournals.jncimonographs.a003477.
[54]
Grulich, A.E.; Leeuwen, M.T.V.; Falster, M.O.; Vajdic, C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007, 370, 59–67, doi:10.1016/S0140-6736(07)61050-2.
[55]
McComsey, G.; Tebas, P.; Shane, E.; Yin, M.T.; Overton, E.T.; Huang, J.S.; Aldrovandi, G.M.; Cardoso, S.W.; Santana, J.L.; Brown, T.T. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin. Infect. Dis. 2010, 51, 937–946.
[56]
Yoon, V.; Maalouf, N.M.; Sakhaee, K. The effects of smoking on bone metabolism. Osteoporos. Int. 2012, 23, 2081–2092.
[57]
Ostrowski, S.R.; Katzenstein, T.L.; Pedersen, B.K.; Gerstoft, J.; Ullum, H. Residual viraemia in HIV-1-infected patients with plasma viral load < or =20 copies？m: Is associated with increased blood levels of soluble immune activation markers. Scand. J. Immunol. 2008, 68, 652–660, doi:10.1111/j.1365-3083.2008.02184.x.
[58]
Kuller, L.H.; Tracy, R.; Belloso, W.; De Wit, S.; Drummond, F.; Lane, H.C.; Ledergerber, B.; Lundgren, J.; Neuhaus, J.; Nixon, D.; et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008, 5, doi:10.1371/journal.pmed.0050203.
[59]
Sandler, N.G.; Wand, H.; Roque, A.; Law, M.; Nason, M.C.; Nixon, D.E.; Pedersen, C.; Ruxurungtham, K.; Lewin, S.R.; Emery, S.; et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 2011, 203, 780–790.
[60]
Maniar, A.; Ellis, C.; Asmuth, D.; Pollard, R.; Rutledge, J. HIV infection and atherosclerosis: Evaluating the drivers of inflammation. Eur. J. Prev. Cardiol. 2012, doi:10.1177/2047487312447843.
[61]
Gazzola, L.; Bellistri, G.M.; Tincati, C.; Lerardi, V.; Savoldi, A.; del Dole, A.; Tagliabue, L.; d’Arminio, M.A.; Marchetti, G. Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J. Transl. Med. 2013, 11, 51, doi:10.1186/1479-5876-11-51.
[62]
Plaeger, S.F.; Collins, B.S.; Musib, R.; Deeks, S.G.; Read, S.; Embry, A. Immune activation in the pathogenesis of treated chronic HIV disease: A workshop summary. AIDS Res. Hum. Retroviruses. 2012, 28, 469–477.
[63]
Ambrose, J.A. The pathophysiology of cigarette smoking and cardiovascular disease. J. Am. Coll. Cardiol. 2004, 43, 1731–1737, doi:10.1016/j.jacc.2003.12.047.
[64]
Hecht, S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91, 1194–1210, doi:10.1093/jnci/91.14.1194.
[65]
Miguez-Burbano, M.J.; Rosenberg, R.; Malow, R.; Burbano, X.; Devieux, J.; Madhavan, N. The effect of mentholated cigarette use on interleukin-6 responses across different HIV positive race/ethnic subgroups. Int. J. Interferon Cytokine Mediator Res. 2010, 2, 157–164.
[66]
Grubb, J.R.; Overton, E.T.; Presti, R.; Onen, N.F. Reply to Ganesan et al. J. Infect. Dis. 2012, 205, 518–519, doi:10.1093/infdis/jir758.
[67]
Vineis, P.; Alavanja, M.; Buffler, P.; Fontham, E.; Franceschi, S.; Gao, Y.T.; Gupta, P.C.; Hackshaw, A.; Matos, E.; Samet, J.; et al. Tobacco and cancer: Recent epidemiological evidence. J. Natl. Cancer Inst. 2004, 96, 99–106.
[68]
Wistuba, I.I.; Behrens, C.; Milchgrub, S.; Virmani, A.K.; Jagirdar, J.; Thomas, B.; Loachim, H.L.; Litzky, L.A.; Brambilla, E.M.; Minna, J.D.; et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 1998, 279, 1554–1559, doi:10.1001/jama.279.19.1554.
[69]
Knowles, D.M. Etiology and pathogenesis of AIDS-related non-Hodgkin’s lymphoma. Hematol. Oncol. Clin. North. Am. 2003, 17, 785–820, doi:10.1016/S0889-8588(03)00050-9.
[70]
Conley, L.J.; Bush, T.J.; Buchbinder, S.P.; Penley, K.A.; Judson, F.N.; Holmberg, S.D. The association between cigarette smoking and selected HIV-related medical conditions. AIDS 1996, 10, 1121–1126.
[71]
Massad, L.S.; Xie, X.; Darragh, T.; Minkoff, H.; Levine, A.M.; Watts, D.H.; Wright, R.L.; D’Souza, G.; Colie, C.; Stickler, H.D. Genital warts and vulvar intraepithelial neoplasia: Natural history and effects of treatment and human immunodeficiency virus infection. Obstet. Gynecol. 2011, 118, 831–839, doi:10.1097/AOG.0b013e31821a0f4d.
[72]
Miguez-Burbano, M.J.; Burbano, X.; Ashkin, D.; Pitchenik, A.; Allan, R.; Pineda, L.; Rodriguez, N.; Shor-Posner, G. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addict. Biol. 2003, 8, 39–43, doi:10.1080/1355621031000069864.
[73]
Palefsky, J.M.; Shiboski, M.A. Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. J. Acquir. Immune Defic. Syndr. 1994, 7, 599–606.
[74]
Turner, J.; Page-Shafer, K.; Chin, D.P.; Osmond, D.; Mossar, M.; Markstein, L.; Huitsing, J.; Barnes, S.; Clemente, V.; Chesney, M.; et al. Adverse impact of cigarette smoking on dimensions of health-related quality of life in persons with HIV infection. AIDS Patient Care 2001, 15, 615–624, doi:10.1089/108729101753354617.
[75]
Furber, S.; Maheswaran, R.; Newell, J.N.; Carroll, C. Is smoking tobacco an independent risk factor for HIV infection and progression to AIDS? A systemic review. Sex Transm. Infect. 2007, 83, 41–46, doi:10.1136/sti.2005.019505.
[76]
Beck, J. Epidemiology of periodontal disease. Curr. Opin. Periodontol. 1996, 3, 3–9.
[77]
Shiboski, C.H.; Neuhaus, J.M.; Greenspan, D.; Greenspan, J.S. Effect of receptive oral sex and smoking on the incidence of hairy leukoplakia in HIV-positive gay men. J. Acquir. Immune Defic. Syndr. 1999, 21, 236–242.
[78]
Burns, D.N.; Hillman, D.; Neaton, J.D.; Sherer, R.; Mitchell, T.; Capps, L.; Vallier, W.G.; Thurnherr, M.D.; Gordin, F.M. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 3, 374–383.
[79]
Palacio, H.; Hilton, J.E.; Canchola, A.J.; Greenspan, D. Effect of cigarette smoking on HIV-related oral lesions. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997, 14, 338–342, doi:10.1097/00042560-199704010-00005.
[80]
Miguez-Burbano, M.J.; Flores, M.; Ashkin, D.; Rodriguez, A.; Granada, A.M.; Quintero, N.; Pitchenik, A. Non-tuberculous mycobacteria disease as a cause of hospitalization in HIV-infected subjects. Int. J. Infect. Dis. 2006, 10, 47–55, doi:10.1016/j.ijid.2004.11.005.
[81]
Hirschtick, R.E.; Glassroth, J.; Jordan, M.C.; Wilcosky, T.C.; Wallace, J.M.; Kvale, P.A.; Markowitz, N.; Rosen, M.J.; Mangura, B.T.; Hopewell, P.C. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N. Engl. J. Med. 1995, 333, 845–851, doi:10.1056/NEJM199509283331305.
Afessa, B. Pleural effusions and pneumothoraces in AIDS. Curr. Opin. Pulm. Med. 2001, 7, 202–209, doi:10.1097/00063198-200107000-00007.
[84]
Palefsky, J.M.; Minkoff, H.; Kalish, L.A.; Levine, A.; Sacks, H.S.; Garcia, P.; Young, M.; Melnick, S.; Miotti, P.; Burk, R. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J. Natl. Cancer Inst. 1999, 91, 26–36.
[85]
Lyketsos, C.G.; Hoover, D.R.; Guccione, M.; Dew, M.A.; Wesch, J.; Bing, E.G.; Treisman, G.J. Depressive symptoms over the course of HIV infection before AIDS. Soc. Psychiatry Psychiatr. Epidemiol. 1996, 31, 212–219, doi:10.1007/BF00785770.
[86]
Crothers, K.; Griffith, T.A.; McGinnis, K.A.; Rodriguez-Barradas, M.C.; Leaf, D.A.; Weissman, S.; Gibert, C.L.; Butt, A.A.; Justice, A.C. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J. Gen. Intern. Med. 2005, 20, 1142–1145, doi:10.1111/j.1525-1497.2005.0255.x.
[87]
Raitakari, O.T.; Juonala, M.; K？h？nen, M.; Taittonen, L.; Laitinen, T.; Maki-Torkko, N.; Jarvisalo, M.J.; Uhari, M.; Jokinen, E.; Ronnemaa, T.; et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood. JAMA 2003, 290, 2277–2283, doi:10.1001/jama.290.17.2277.
[88]
Bhuiyan, A.R.; Srinivasan, S.R.; Chen, W.; Paul, T.K.; Berenson, G.S. Correlates of vascular structure and function measures in asymptomatic young adults: The Bogalusa heart study. Atherosclerosis 2006, 189, 1–7, doi:10.1016/j.atherosclerosis.2006.02.011.
[89]
Kallio, K.; Jokinen, E.; Raitakari, O.T.; H？m？l？inen, M.; Siltala, M.; Volanen, I.; Kaitosaari, T.; Viikari, J.; R？nnemaa, T.; Simell, O. Tobacco smoke exposure is associated with attenuated endothelial function in 11-year-old healthy children. Circulation 2007, 115, 3205–3212, doi:10.1161/CIRCULATIONAHA.106.674804.
[90]
Wang, X.; Mensinga, T.T.; Schouten, J.P.; Rijcken, B.; Weiss, S.T. Determinants of maximally attained level of pulmonary Function. Am. J. Respir. Crit. Care Med. 2004, 169, 941–949, doi:10.1164/rccm.2201011.
[91]
Mallol, J.; Castro-Rodriguez, J.A.; Cortez, E. Effects of active tobacco smoking on the prevalence of asthma-like symptoms in adolescents. Int. J. Chron. Obstruct Pulmon. Dis. 2007, 2, 65–69.
[92]
United States Department of Health and Human Services. Report of the Surgeon General: Preventing Tobacco Use among Young People. 1994. Available online: http://www.who.int/tobacco/research/youth/health_effects/en/index.html (accessed on 18 March 2013).
[93]
Johnson, J.L.; Eaton, D.K.; Pederson, L.L.; Lowry, R. Associations of trying to lose weight, weight control behaviors, and current cigarette use among US high school student. J. Sch. Health 2009, 79, 355–360, doi:10.1111/j.1746-1561.2009.00421.x.
[94]
United States Department of Health and Human Services. Report of the Surgeon General: Women and Smoking. 2001. Available online: http://www.surgeongeneral.gov/library/reports/womenandtobacco/index.html (accessed on 18 March 2013).
[95]
Anderson, H.R.; Cook, D.G. Passive smoking and sudden infant death syndrome: Review of the epidemiological evidence. Thorax 1997, 52, 1003–1009, doi:10.1136/thx.52.11.1003.
[96]
Center for Disease Control and Prevention (CDC). Infant Mortality in the US: Where We Stand. Available online: http://www.cdc.gov/about/grand-rounds/archives/2012/pdfs/GR_Infant_Mortality_Final_Oct16.pdf (accessed on 25 March 2013).
[97]
Cooper, E.R.; Charurat, M.; Mofenson, L.; Hanson, I.C.; Pitt, J.; Diaz, C.; Hayani, K.; Handelsman, E.; Smeriglio, V.; Hoff, R.; et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and preventioin of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 2002, 29, 484–494.
[98]
Connor, E.M.; Sperling, R.S.; Gelber, R.; Kiselev, P.; Scott, G.; O’Sullivan, M.J.; van Dyke, R.; Bey, M.; Shearer, W.; Jacobson, R.L.; et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatmentPediatric AIDS clinical trials group protocol 076 study group. N. Engl. J. Med. 1994, 331, 1173–1180, doi:10.1056/NEJM199411033311801.
[99]
Burns, D.N.; Landesman, S. Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J. Acquir. Immune Defic. Syndr. 1994, 7, 718–726.
Piper, M.E.; Smith, S.S.; Schlam, T.R.; Fleming, M.F.; Bittrick, A.A.; Brown, J.L.; Leitzke, C.J.; Zehner, M.E.; Fiore, M.C.; Baker, T.B. Psychiatric disorders in smokers seeking treatment for tobacco dependence: Relations with tobacco dependence and cessation. J. Consult. Clin. Psychol. 2010, 78, 13–23, doi:10.1037/a0018065.
[102]
Humfleet, G.; Mu？oz, R.; Sees, K.; Reus, V.; Hall, S. History of alcohol or drug problems, current use of alcohol or marijuana, and success in quitting smoking. Addict. Behav. 1999, 24, 149–154, doi:10.1016/S0306-4603(98)00057-4.
[103]
Humfleet, G.L.; Delucchi, K.; Kelley, K.; Hall, S.M.; Dilley, J. Characteristics of HIV-positive cigarette smokers: A sample of smokers facing multiple challenges. AIDS Educ. Prev. 2009, 21, 54–64, doi:10.1521/aeap.2009.21.3_supp.54.
[104]
Bing, E.G.; Burnam, M.A.; Longshore, D.; Fleishman, J.A.; Sherbourne, C.D.; London, A.S.; Turner, B.J.; Eggan, F.; Beckman, R.; Vitiello, B.; et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch. Gen. Psychiatry 2001, 58, 721–728, doi:10.1001/archpsyc.58.8.721.
[105]
Shacham, E.; Nurutdinova, D.; Satyanarayana, V.; Stamm, K.; Overton, E.T. Routine screening for depression: Identifying a challenge for successful HIV care. Aids Patient Care 2009, 23, 949–955, doi:10.1089/apc.2009.0064.
[106]
Shacham, E.; Morgan, J.; Onen, N.; Taniguchi, T.; Overton, E.T. Screening anxiety in the HIV Clinic. AIDS Behav. 2012, 16, 2407–2413, doi:10.1007/s10461-012-0238-6.
[107]
Cofrancesco, J.; Scherzer, R.; Tien, P.C.; Gibert, C.L.; Southwell, H.; Sidney, S.; Dobs, A.; Grunfeld, C. Illicit drug use and HIV treatment outcomes in a US cohort. AIDS 2008, 22, 357–365, doi:10.1097/QAD.0b013e3282f3cc21.
[108]
Harris, J.K. Connecting discovery and delivery: The need for more evidence on effective smoking cessation strategies for people living with HIV/AIDS. Am. J. Public Health 2010, 100, 1245–1249, doi:10.2105/AJPH.2009.172460.
[109]
Hurt, R.D.; Sachs, D.P.; Glover, E.D.; Offord, K.P.; Johnston, J.A.; Dale, L.C.; Khayrallah, M.A.; Schroeder, D.R.; Glover, P.N.; Sullivan, C.R.; et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 1997, 337, 1195–1202, doi:10.1056/NEJM199710233371703.
[110]
Fossati, R.; Apolone, G.; Negri, E.; Compagnoni, A.; La Vecchia, C.; Mangano, S.; Clivio, L.; Garattini, S. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch. Int. Med. 2007, 167, 1791–1797, doi:10.1001/archinte.167.16.1791.
[111]
Gonzales, D.; Rennard, S.I.; Nides, M.; Oncken, C.; Azoulay, S.; Billing, C.B.; Watsky, E.J.; Gong, J.; Williams, K.E.; Reeves, K.R. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006, 296, 47–55, doi:10.1001/jama.296.1.47.
[112]
Jorenby, D.E.; Hays, J.T.; Rigotti, N.A.; Azoulay, S.; Watsky, E.J.; Williams, K.E.; Billing, C.B.; Gong, J.; Reeves, K.R. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006, 296, 56–63, doi:10.1001/jama.296.1.56.
[113]
Wewers, M.E.; Neidig, J.L. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. J. Assoc. Nurses AIDS Care 2006, 11, 37–44, doi:10.1016/S1055-3290(06)60353-1.
[114]
Lazev, A.; Vidrine, D.; Arduino, R.; Gritz, E. Increasing access to smoking cessation treatment in a low-income, HIV-positive population: The feasibility of using cellular telephones. Nicotine Tob. Res. 2004, 6, 281–286, doi:10.1080/14622200410001676314.
[115]
Elzi, L.; Spoerl, D.; Voggensperger, J.; Nicca, D.; Simcock, M.; Bucher, H.C.; Spirig, R.; Battegay, M. A smoking cessation programme in HIV-infected individuals: Pilot study. Antivir. Ther. 2006, 11, 787–795.
[116]
Pedrol-Clotet, E.; Deig-Comerma, E.; Ribell-Bachs, M.; Vidal-Castell, I.; Garcia-Rodriguez, P. Buproprion use for smoking cessation in HIV-infected patients receiving antiretroviral therapy. Enferm. Infecc. Microbiol. Clin. 2006, 24, 509–511, doi:10.1157/13092468.
[117]
Ingersoll, K.S.; Cropsey, K. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009, 13, 545–554, doi:10.1007/s10461-007-9334-4.
[118]
118. Lloyd-richardson, E.E.; Stanton, C.A.; Papandonatos, G.D.; Shadel, W.G.; Stein, M.; Tashima, K.; Flanigan, T.; Morrow, K.; Neighbors, C.; Niaura, R. Motivation and patch treatment for HIV+ smokers: A randomized controlled trial. Addiction 2009, 104, 1891–1900, doi:10.1111/j.1360-0443.2009.02623.x.
[119]
Tornero, C. Varenicline and antiretroviral therapy in patients with HIV. J. Acquir. Immune Defic. Syndr. 2009, 52, 655–661, doi:10.1097/QAI.0b013e3181ba1beb.
[120]
Moadel, A.B.; Bernstein, S.L.; Mermelstein, R.J.; Arnsten, J.H.; Dolce, E.H.; Shuter, J. A randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J. Acquir. Immune Defic. Syndr. 2012, 61, 208–215, doi:10.1097/QAI.0b013e3182645679.
[121]
Cui, Q.; Robinson, L.; Elston, D. Safety and tolerability of varenicline tartrate (Champix(？)/Chantix(？) for smoking cessation in HIV-infected subjects: A pilot open-label study. AIDS Patient Care STDS 2012, 26, 12–19, doi:10.1089/apc.2011.0199.
[122]
Manuel, J.K.; Lum, P.J.; Hengl, N.S.; Sorensen, J.L. Smoking cessation interventions with female smokers living with HIV/AIDS: A randomized pilot study of motivational interviewing. AIDS Care 2012, 11, 37–41.
[123]
Farkas, A.J.; Distefan, J. Does parental smoking cessation discourage adolescent smoking? Prev. Med. 1999, 218, 213–218, doi:10.1006/pmed.1998.0451.
[124]
Kim, M.J.; Fleming, C.B.; Catalano, R.F. Individual and social influences on progression to daily smoking during adolescence. Pediatrics 2009, 124, 895–902, doi:10.1542/peds.2008-2015.
[125]
Vitaro, F.; Wanner, B.; Brendgen, M.; Gosselin, C.; Gendreau, P.L. Differential contribution of parents and friends to smoking trajectories during adolescence. Addict. Behav. 2004, 29, 831–835, doi:10.1016/j.addbeh.2004.02.018.
[126]
Treating Tobacco Use and Dependence2008 Update. Available online: http://www.ncbi.nlm.nih.gov/books/NBK63960/#A28506 (accessed on 18 March 2013).
[127]
Sims, T.H.; Meurer, J.R.; Sims, M.; Layde, P.M. Factors associated with physician interventions to address adolescent smoking. Health Serv. Res. 2004, 39, 571–586, doi:10.1111/j.1475-6773.2004.00245.x.
Sussman, S.; Sun, P.; Dent, C.W. A meta-analysis of teen cigarette smoking cessation. Health Psychol. 2006, 25, 549–557, doi:10.1037/0278-6133.25.5.549.
[130]
Not-On-Tobacco (N-O-T), Available online: www.notontobacco.com (accessed on 18 March 2013).
[131]
Grimshaw, S.A. Tobacco cessation interventions for young people. Cochrane Database Syst. Rev. 2006, doi:10.1002/14651858.CD003289.pub4.
[132]
Prokhorov, A.V. Theoretically sound approaches to prevention and cessation of cigarette smoking among youths. Pediatr. Pulmonol. 2001, 23, 57–59.
[133]
Armitage, C.J.; Arden, M.A. How useful are the stages of change for targeting interventions? Randomized test of a brief intervention to reduce smoking. Health Psychol. 2008, 27, 789–798, doi:10.1037/0278-6133.27.6.789.
[134]
Colby, SM, Monti; O’Leary, T.; Barnett, N.P.; Spirito, A.; Rohsenhow, D.J.; Riggs, S.; Lewander, W. Brief motivational intervention for adolescent smokers in medical settings. Addict. Behav. 2005, 30, 865–874, doi:10.1016/j.addbeh.2004.10.001.
[135]
Difranza, J.R.; Sweet, M.; Savageau, J.; Ursprung, W.W. An evaluation of a clinical approach to staging tobacco addiction. J. Pediatr. 2011, 159, 999–1003, doi:10.1016/j.jpeds.2011.05.037.
[136]
Moolchan, E.T.; Robinson, M.L.; Ernst, M.; Cadet, J.L.; Pickworth, W.B.; Heishman, S.J.; Schroeder, J.R. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 2005, 115, e407–e414, doi:10.1542/peds.2004-1894.
[137]
Hanson, K.; Allen, S.; Jensen, S.; Hatsukami, D. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob. Res. 2003, 5, 515–526.
[138]
Niederhofer, H.; Huber, M. Bupropion may support psychosocial treatment of nicotine-dependent adolescents: Preliminary results. Pharmacotherapy 2004, 24, 1524–1548, doi:10.1592/phco.24.16.1524.50953.
[139]
Killen, J.D.; Robinson, T.N.; Ammerman, S.; Hayward, C.; Rogers, J.; Stone, C.; Samuels, D.; Levin, S.K.; Green, S.A. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J. Consult. Clin. Psychol. 2004, 72, 729–735, doi:10.1037/0022-006X.72.4.729.
Faessel, H.; Ravva, P.; Williams, K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: A multicenter, randomized, double-blind. Clin. Ther. 2009, 31, 177–189, doi:10.1016/j.clinthera.2009.01.003.
[142]
Hollis, J.F.; Polen, M.R.; Lichtenstein, E.; Whitlock, E.P. Tobacco use patterns and attitudes among teens being seen for routine primary care. Am. J. Health Promot. 2003, 17, 231–239, doi:10.4278/0890-1171-17.4.231.
[143]
Center for Disease Control and Prevention (CDC). Use of cessation methods among smokers aged 16-24 years-United States, 2003. MMWR Morb. Mortal Wkly. Rep. 2006, 55, 1351–1354.
[144]
Center for Disease Control and Prevention (CDC). High school students who tried to quit smoking cigarettes-United States, 2007. MMWR Morb. Mortal Wkly. Rep. 2009, 58, 428–431, doi:10.1037/e551902010-002.
[145]
Fingerhut, L.A.; Kleinman, K.J. Smoking before, during, and after pregnancy. Am. J. Public Health 1990, 80, 541–544, doi:10.2105/AJPH.80.5.541.
Lumley, J.; Chamberlain, C.; Dowswell, T. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD001055.pub3.
[148]
Donatelle, R.J.; Prows, S.L.; Champeau, D.; Hudson, D. Randomised controlled trial using social support and financial incentives for high risk pregnant smokers: Significant Other Supporter (SOS) program. Tob. Control. 2000, 9, 67–69.
[149]
Heil, S.H.; Higgins, S.T.; Bernstein, I.M.; Solomon, L.J.; Rogers, R.E.; Thomas, C.S.; Badger, G.J.; Lynch, M.E. Effects of voucher-based incentives on abstinence from cigarette smoking and fetal growth among pregnant women. Addiction 2008, 103, 1009–1018, doi:10.1111/j.1360-0443.2008.02237.x.
[150]
Maritz, G.S. Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring. Ther. Adv. Respir. Dis. 2009, 3, 193–210, doi:10.1177/1753465809343712.
[151]
Dempsey, D.A. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf. 2001, 24, 277–322, doi:10.2165/00002018-200124040-00005.
[152]
Morales-Suárez-Varela, M.M.; Bille, C.; Christensen, K. Smoking habits, nicotine use, and congenital malformations. Obstet. Gynecol. 2006, 107, 51–57, doi:10.1097/01.AOG.0000194079.66834.d5.
[153]
Davidson, P. Smoking habits, nicotine use, and congenital malformations. Obstet. Gynecol. 2006, 107, 1166–1167, doi:10.1097/01.AOG.0000218110.92605.18.
[154]
Pollak, K.I.; Oncken, C.A.; Lipkus, I.M.; Lyna, P.; Swamy, G.K.; Pletsch, P.K.; Peterson, B.L.; Heine, R.P.; Brouwer, R.J.; Fish, L.; et al. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am. J. Prev. Med. 2007, 33, 297–305, doi:10.1016/j.amepre.2007.05.006.
[155]
Gaither, K.H.; Huber, L.R.; Thompson, M.E.; Huet-Hudson, Y.M. Does the use of nicotine replacement therapy during pregnancy affect pregnancy outcomes? Matern. Child. Health J. 2009, 13, 497–504, doi:10.1007/s10995-008-0361-1.
[156]
The American College of Obstetricians and Gynecologists. Smoking cessation during pregnancy. Obstet. Gynecol. 2010, 116, 1241–1244, doi:10.1097/AOG.0b013e3182004fcd.
[157]
Rore, C.; Brace, V.; Danielian, P.; Williams, D. Smoking cessation in pregnancy. Expert Opin. Drug Saf. 2008, 7, 727–737, doi:10.1517/14740330802196756.
[158]
Coleman, T.; Chamberlain, C.; Davey, M.A.; Cooper, S.E.; Leonardi-Bee, J. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst. Rev. 2012, doi:10.1002/14651858.CD010078.
[159]
Chun-Fai-Chan, B.; Koren, G.; Fayez, I.; Kalra, S.; Voyer-Lavigne, S.; Boshier, A.; Shakir, S.; Einarson, A. Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am. J. Obstet. Gynecol. 2005, 192, 932–936, doi:10.1016/j.ajog.2004.09.027.
[160]
Cole, J.A.; Modell, J.G.; Haight, B.R.; Cosmatos, I.S.; Stoler, J.M.; Walker, A.M. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol. Drug Saf. 2007, 16, 474–484, doi:10.1002/pds.1296.
[161]
Diclemente, C.C.; Dolan-Mullen, P.; Windsor, R.A. The process of pregnancy smoking cessation: Implications for interventions. Tob. Control. 2000, 9, 16–21, doi:10.1136/tc.9.1.16.
[162]
Stotts, A.L.; DiClemente, C.C.; Carbonari, J.P.; Mullen, P.D. Pregnancy smoking cessation: A case of mistaken identity. Addict. Behav. 1996, 21, 459–471, doi:10.1016/0306-4603(95)00082-8.
[163]
Wall, M.A.; Severson, H.H.; Andrews, J.A.; Lichtenstein, E.; Zoref, L. Pediatric office-based smoking intervention: Impact on maternal smoking and relapse. Pediatrics 1995, 96, 622–628.
[164]
Curry, S.J.; Ludman, E.J.; Graham, E.; Stout, J.; Grothaus, L.; Lozano, P. Pediatric-based smoking cessation intervention for low-income women: A randomized trial. Arch. Pediatr. Adolesc. Med. 2003, 157, 295–302, doi:10.1001/archpedi.157.3.295.
[165]
Winickoff, J.P.; Buckley, V.J.; Palfrey, J.S.; Perrin, J.M.; Rigotti, N.A. Intervention with parental smokers in an outatient pediatric clinic using counseling and nicotine replacement. Pediatrics 2003, 112, 1127–1133, doi:10.1542/peds.112.5.1127.
[166]
American Medical Association (AMA). Policy Finder. Available online: http://www.ama-assn.org/ama/pub/about-ama/our-people/house-delegates/policyfinder.page (accessed on 18 March 2013).
[167]
Orleans, C.T.; Barker, D.C.; Kaufman, N.J.; Marx, J.F. Helping pregnant smokers quit: Meeting the challenge in the next decade. Tob. Control. 2000, 9, 6–11.
[168]
Center for Disease Control and Prevention (CDC). Quitting smoking among adults-United States, 2001-2010. MMWR Morb. Mortal. Wkly. 2011, 60, 1513–1519.
[169]
Doll, R.; Peto, R.; Boreham, J.; Sutherland, I. Mortality in relation to smoking: 50 years’ observations observations on male British doctors. BMJ 2004, 328, 1519, doi:10.1136/bmj.38142.554479.AE.
